Truist Ignites Excitement for Rapport Therapeutics (RAPP) with New 'Buy' Rating and $21 Price Target
Cybersecurity Shifts: CrowdStrike Faces Price Adjustments, Verint Acquires Teneo, and Netskope Nears IPO
Brixmor Property Group Under the Microscope: Decoding Analyst Sentiments